{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T13:09:26Z","timestamp":1792069766760,"version":"4.4.0"},"reference-count":48,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2016,4,1]],"date-time":"2016-04-01T00:00:00Z","timestamp":1459468800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,4,1]],"date-time":"2016-04-01T00:00:00Z","timestamp":1459468800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","joms.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Oral and Maxillofacial Surgery"],"published-print":{"date-parts":[[2016,4]]},"DOI":"10.1016\/j.joms.2015.09.028","type":"journal-article","created":{"date-parts":[[2015,10,9]],"date-time":"2015-10-09T02:42:04Z","timestamp":1444358524000},"page":"738-746","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":28,"title":["Serum Markers of Bone Turnover and Angiogenesis in Patients With Bisphosphonate-Related Osteonecrosis of the Jaw After Discontinuation of Long-Term Intravenous Bisphosphonate Therapy"],"prefix":"10.1016","volume":"74","author":[{"given":"Vivek","family":"Thumbigere-Math","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bryan S.","family":"Michalowicz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pamela J.","family":"Hughes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David L.","family":"Basi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michaela L.","family":"Tsai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen K.","family":"Swenson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Rockwell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajaram","family":"Gopalakrishnan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.joms.2015.09.028_bib1","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/j.joms.2004.02.004","article-title":"Osteonecrosis of the jaws associated with the use of bisphosphonates: A\u00a0review of 63 cases","volume":"62","author":"Ruggiero","year":"2004","journal-title":"J Oral Maxillofac Surg"},{"key":"10.1016\/j.joms.2015.09.028_bib2","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1016\/j.joms.2005.07.010","article-title":"Bisphosphonate-induced exposed bone (osteonecrosis\/osteopetrosis) of the jaw: Risk factors, recognition, prevention, and treatment","volume":"63","author":"Marx","year":"2005","journal-title":"J\u00a0Oral Maxillofac Surg"},{"key":"10.1016\/j.joms.2015.09.028_bib3","doi-asserted-by":"crossref","first-page":"753","DOI":"10.7326\/0003-4819-144-10-200605160-00009","article-title":"Narrative [corrected] review: Bisphosphonates and osteonecrosis of the jaws","volume":"144","author":"Woo","year":"2006","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.joms.2015.09.028_bib4","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1002\/cncr.21130","article-title":"Bisphosphonate-associated osteonecrosis of mandibular and maxillary bone: An emerging oral complication of supportive cancer therapy","volume":"104","author":"Migliorati","year":"2005","journal-title":"Cancer"},{"key":"10.1016\/j.joms.2015.09.028_bib5","first-page":"1080","article-title":"Pamidronate induces modifications of circulating angiogenic factors in cancer patients","volume":"8","author":"Santini","year":"2002","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.joms.2015.09.028_bib6","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1093\/annonc\/mdg194","article-title":"Bisphosphonates: New antiangiogenic molecules in cancer treatment?","volume":"14","author":"Vincenzi","year":"2003","journal-title":"Ann Oncol"},{"key":"10.1016\/j.joms.2015.09.028_bib7","series-title":"Bisphosphonat-Manual","first-page":"83","author":"Bartl","year":"2006"},{"key":"10.1016\/j.joms.2015.09.028_bib8","first-page":"237","article-title":"Effect of pamidronate on bone blood flow in oophorectomized rats","volume":"47","author":"Kapitola","year":"1998","journal-title":"Physiol Res"},{"key":"10.1016\/j.joms.2015.09.028_bib9","doi-asserted-by":"crossref","first-page":"2397","DOI":"10.1016\/j.joms.2007.08.003","article-title":"Oral bisphosphonate-induced osteonecrosis: Risk factors, prediction of risk using serum CTX testing, prevention, and treatment","volume":"65","author":"Marx","year":"2007","journal-title":"J Oral Maxillofac Surg"},{"key":"10.1016\/j.joms.2015.09.028_bib10","doi-asserted-by":"crossref","first-page":"2241","DOI":"10.1016\/j.joms.2010.05.043","article-title":"Serologic bone markers for predicting development of osteonecrosis of the jaw in patients receiving bisphosphonates","volume":"68","author":"Lazarovici","year":"2010","journal-title":"J Oral Maxillofac Surg"},{"key":"10.1016\/j.joms.2015.09.028_bib11","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.joms.2008.09.015","article-title":"Bisphosphonate-induced osteonecrosis of the jaws, bone markers, and a hypothesized candidate gene","volume":"67","author":"Lehrer","year":"2009","journal-title":"J Oral Maxillofac Surg"},{"key":"10.1016\/j.joms.2015.09.028_bib12","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1186\/1756-8722-5-56","article-title":"Serum VEGF levels as predictive marker of bisphosphonate-related osteonecrosis of the jaw","volume":"5","author":"Vincenzi","year":"2012","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.joms.2015.09.028_bib13","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.14219\/jada.archive.2011.0108","article-title":"Managing the care of patients receiving antiresorptive therapy for prevention and treatment of osteoporosis: Executive summary of recommendations from the American Dental Association Council on Scientific Affairs","volume":"142","author":"Hellstein","year":"2011","journal-title":"J Am Dent Assoc"},{"key":"10.1016\/j.joms.2015.09.028_bib14","first-page":"2","article-title":"American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws\u20142009 update","volume":"67","author":"Ruggiero","year":"2009","journal-title":"J Oral Maxillofac Surg"},{"key":"10.1016\/j.joms.2015.09.028_bib15","first-page":"1391","article-title":"Canadian consensus practice guidelines for bisphosphonate associated osteonecrosis of the jaw","volume":"35","author":"Khan","year":"2008","journal-title":"J Rheumatol"},{"key":"10.1016\/j.joms.2015.09.028_bib16","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1902\/jop.2013.130017","article-title":"Periodontal disease as a risk factor for bisphosphonate-related osteonecrosis of the jaw","volume":"85","author":"Thumbigere-Math","year":"2014","journal-title":"J Periodontol"},{"key":"10.1016\/j.joms.2015.09.028_bib17","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1007\/PL00005830","article-title":"Serum CTX: A new marker of bone resorption that shows treatment effect more often than other markers because of low coefficient of variability and large changes with bisphosphonate therapy","volume":"66","author":"Rosen","year":"2000","journal-title":"Calcif Tissue Int"},{"key":"10.1016\/j.joms.2015.09.028_bib18","doi-asserted-by":"crossref","first-page":"2290","DOI":"10.1093\/clinchem\/44.11.2290","article-title":"Clinical evaluation of the Serum CrossLaps One Step ELISA, a new assay measuring the serum concentration of bone-derived degradation products of type I collagen C-telopeptides","volume":"44","author":"Christgau","year":"1998","journal-title":"Clin Chem"},{"key":"10.1016\/j.joms.2015.09.028_bib19","doi-asserted-by":"crossref","first-page":"2644","DOI":"10.1016\/j.joms.2009.04.067","article-title":"Correlation between serum C-terminal cross-linking telopeptide of type I collagen and staging of oral bisphosphonate-related osteonecrosis of the jaws","volume":"67","author":"Kwon","year":"2009","journal-title":"J\u00a0Oral Maxillofac Surg"},{"key":"10.1016\/j.joms.2015.09.028_bib20","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1016\/j.joms.2014.02.036","article-title":"A C-terminal crosslinking telopeptide test-based protocol for patients on oral bisphosphonates requiring extraction: A prospective single-center controlled study","volume":"72","author":"Hutcheson","year":"2014","journal-title":"J Oral Maxillofac Surg"},{"key":"10.1016\/j.joms.2015.09.028_bib21","doi-asserted-by":"crossref","first-page":"e367","DOI":"10.4317\/medoral.17583","article-title":"Study of serum CTX in 50 oral surgical patients treated with oral bisphosphonates","volume":"17","author":"Flichy-Fernandez","year":"2012","journal-title":"Med Oral Patol Oral Cir Bucal"},{"key":"10.1016\/j.joms.2015.09.028_bib22","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1016\/j.oraloncology.2008.01.012","article-title":"Collagen telopeptide (serum CTX) and its relationship with the size and number of lesions in osteonecrosis of the jaws in cancer patients on intravenous bisphosphonates","volume":"44","author":"Bagan","year":"2008","journal-title":"Oral Oncol"},{"key":"10.1016\/j.joms.2015.09.028_bib23","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1016\/j.joms.2009.02.004","article-title":"Clinical investigation of C-terminal cross-linking telopeptide test in prevention and management of bisphosphonate-associated osteonecrosis of the jaws","volume":"67","author":"Kunchur","year":"2009","journal-title":"J Oral Maxillofac Surg"},{"key":"10.1016\/j.joms.2015.09.028_bib24","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1016\/j.joms.2008.01.054","article-title":"Oral bisphosphonate-induced osteonecrosis: Risk factors, prediction of risk using serum CTX testing, prevention, and treatment","volume":"66","author":"Khosla","year":"2008","journal-title":"J Oral Maxillofac Surg"},{"key":"10.1016\/j.joms.2015.09.028_bib25","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1016\/j.joms.2007.12.048","article-title":"Serum CTX testing","volume":"66","author":"Schwartz","year":"2008","journal-title":"J Oral Maxillofac Surg"},{"key":"10.1016\/j.joms.2015.09.028_bib26","doi-asserted-by":"crossref","first-page":"3955","DOI":"10.1158\/1078-0432.CCR-14-0434","article-title":"Biomarkers of bone remodeling in multiple myeloma patients to tailor bisphosphonate therapy","volume":"20","author":"Patel","year":"2014","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.joms.2015.09.028_bib27","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1016\/j.bone.2012.03.016","article-title":"Five years of anti-resorptive activity after a single dose of zoledronate\u2014Results from a randomized double-blind placebo-controlled trial","volume":"50","author":"Grey","year":"2012","journal-title":"Bone"},{"key":"10.1016\/j.joms.2015.09.028_bib28","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1002\/jbmr.2442","article-title":"The effect of 6 versus 9 years of zoledronic acid treatment in osteoporosis: A randomized second extension to the HORIZON-Pivotal Fracture Trial (PFT)","volume":"30","author":"Black","year":"2015","journal-title":"J\u00a0Bone Miner Res"},{"key":"10.1016\/j.joms.2015.09.028_bib29","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.jbo.2012.07.002","article-title":"The ZOTECT study: Effect of zoledronic acid on bone metabolism in patients with bone metastases from prostate or breast cancer","volume":"1","author":"Hadji","year":"2012","journal-title":"J Bone Oncol"},{"key":"10.1016\/j.joms.2015.09.028_bib30","doi-asserted-by":"crossref","first-page":"9111","DOI":"10.1200\/jco.2012.30.15_suppl.9111","article-title":"Continued suppression of bone turnover following a single dose of zoledronic acid: Time to re-think dosing intervals in the management of bone metastases?","volume":"30","author":"Simmons","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.joms.2015.09.028_bib31","doi-asserted-by":"crossref","first-page":"2927","DOI":"10.1001\/jama.296.24.2927","article-title":"Effects of continuing or stopping alendronate after 5 years of treatment: The Fracture Intervention Trial Long-term Extension (FLEX): A randomized trial","volume":"296","author":"Black","year":"2006","journal-title":"JAMA"},{"key":"10.1016\/j.joms.2015.09.028_bib32","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1002\/jbmr.1494","article-title":"The effect of 3 versus 6 years of zoledronic acid treatment of osteoporosis: A randomized extension to the HORIZON-Pivotal Fracture Trial (PFT)","volume":"27","author":"Black","year":"2012","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.joms.2015.09.028_bib33","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1001\/jamainternmed.2014.1232","article-title":"Fracture prediction after discontinuation of 4 to 5 years of alendronate therapy: The FLEX study","volume":"174","author":"Bauer","year":"2014","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.joms.2015.09.028_bib34","doi-asserted-by":"crossref","first-page":"989","DOI":"10.4158\/EP12425.OR","article-title":"Long-term follow-up of patients on drug holiday from bisphosphonates: Real-world setting","volume":"19","author":"Chiha","year":"2013","journal-title":"Endocr Pract"},{"key":"10.1016\/j.joms.2015.09.028_bib35","doi-asserted-by":"crossref","first-page":"31","DOI":"10.11005\/jbm.2013.20.1.31","article-title":"Effects of a \u2018drug holiday\u2019 on bone mineral density and bone turnover marker during bisphosphonate therapy","volume":"20","author":"Kong","year":"2013","journal-title":"J Bone Metab"},{"key":"10.1016\/j.joms.2015.09.028_bib36","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/8756-3282(95)00445-9","article-title":"Bisphosphonates: A review of their pharmacokinetic properties","volume":"18","author":"Lin","year":"1996","journal-title":"Bone"},{"key":"10.1016\/j.joms.2015.09.028_bib37","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1111\/j.1600-0501.2010.01965.x","article-title":"Retrospective study of two biochemical markers for the risk assessment of oral bisphosphonate-related osteonecrosis of the jaws: Can they be utilized as risk markers?","volume":"22","author":"Kwon","year":"2011","journal-title":"Clin Oral Implants Res"},{"key":"10.1016\/j.joms.2015.09.028_bib38","doi-asserted-by":"crossref","first-page":"2768","DOI":"10.1016\/j.joms.2011.12.028","article-title":"Serum N-telopeptide and bone-specific alkaline phosphatase levels in patients with osteonecrosis of the jaw receiving bisphosphonates for bone metastases","volume":"70","author":"Morris","year":"2012","journal-title":"J Oral Maxillofac Surg"},{"key":"10.1016\/j.joms.2015.09.028_bib39","doi-asserted-by":"crossref","first-page":"2387","DOI":"10.1158\/1078-0432.CCR-07-1430","article-title":"Clinical, radiographic, and biochemical characterization of multiple myeloma patients with osteonecrosis of the jaw","volume":"14","author":"Raje","year":"2008","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.joms.2015.09.028_bib40","first-page":"2012","article-title":"Effects of intravenous zoledronate on bone turnover and bone density persist for at least five years in HIV-infected men","volume":"97","author":"Bolland","year":"1922","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.joms.2015.09.028_bib41","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.tripleo.2011.02.028","article-title":"Differential impairment of vascularization and angiogenesis in bisphosphonate-associated osteonecrosis of the jaw-related mucoperiosteal tissue","volume":"112","author":"Wehrhan","year":"2011","journal-title":"Oral Surg Oral Med Oral Pathol Oral Radiol Endod"},{"key":"10.1016\/j.joms.2015.09.028_bib42","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1111\/j.1600-0714.2010.01004.x","article-title":"Vascular endothelial growth factor genetic polymorphisms and haplotypes in female patients with bisphosphonate-related osteonecrosis of the jaws","volume":"40","author":"Arduino","year":"2011","journal-title":"J Oral Pathol Med"},{"key":"10.1016\/j.joms.2015.09.028_bib43","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1159\/000201931","article-title":"Combination of bisphosphonates and antiangiogenic factors induces osteonecrosis of the jaw more frequently than bisphosphonates alone","volume":"76","author":"Christodoulou","year":"2009","journal-title":"Oncology"},{"key":"10.1016\/j.joms.2015.09.028_bib44","doi-asserted-by":"crossref","first-page":"4037","DOI":"10.1200\/JCO.2007.15.5424","article-title":"Osteonecrosis of the jaw related to bevacizumab","volume":"26","author":"Estilo","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.joms.2015.09.028_bib45","doi-asserted-by":"crossref","first-page":"e2","DOI":"10.1016\/j.oraloncology.2011.07.030","article-title":"A case report of bevacizumab-related osteonecrosis of the jaw: Old problem, new culprit","volume":"48","author":"Disel","year":"2012","journal-title":"Oral Oncol"},{"key":"10.1016\/j.joms.2015.09.028_bib46","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1007\/s10006-010-0224-y","article-title":"Osteonecrosis of the jaw related to sunitinib","volume":"15","author":"Koch","year":"2011","journal-title":"Oral Maxillofac Surg"},{"key":"10.1016\/j.joms.2015.09.028_bib47","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1016\/j.tripleo.2011.06.023","article-title":"Sunitinib related osteonecrosis of jaw: A case report","volume":"113","author":"Fleissig","year":"2012","journal-title":"Oral Surg Oral Med Oral Pathol Oral Radiol"},{"key":"10.1016\/j.joms.2015.09.028_bib48","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1097\/COC.0b013e3182155fcb","article-title":"A retrospective study evaluating frequency and risk factors of osteonecrosis of the jaw in 576 cancer patients receiving intravenous bisphosphonates","volume":"35","author":"Thumbigere-Math","year":"2012","journal-title":"Am J Clin Oncol"}],"container-title":["Journal of Oral and Maxillofacial Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0278239115012963?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0278239115012963?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T16:48:26Z","timestamp":1759510106000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0278239115012963"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,4]]},"references-count":48,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2016,4]]}},"alternative-id":["S0278239115012963"],"URL":"https:\/\/doi.org\/10.1016\/j.joms.2015.09.028","relation":{},"ISSN":["0278-2391"],"issn-type":[{"value":"0278-2391","type":"print"}],"subject":[],"published":{"date-parts":[[2016,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Serum Markers of Bone Turnover and Angiogenesis in Patients With Bisphosphonate-Related Osteonecrosis of the Jaw After Discontinuation of Long-Term Intravenous Bisphosphonate Therapy","name":"articletitle","label":"Article Title"},{"value":"Journal of Oral and Maxillofacial Surgery","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.joms.2015.09.028","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2016 American Association of Oral and Maxillofacial Surgeons. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}